Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Comparative Effectiveness of Dulaglutide, Semaglutide, and Tirzepatide in Preventing Cardiovascular Events in Patients With Type 2 Diabetes and Obesity With or Without Atherosclerotic Cardiovascular Disease.

NCT07417618 is registered in ClinicalTrials.gov with Brigham and Women's Hospital as lead sponsor.

NCT NCT07417618
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07417618 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Comparative Effectiveness of Dulaglutide, Semaglutide, and Tirzepatide in Preventing Cardiovascular Events in Patients With Type 2 Diabetes and Obesity With or Without Atherosclerotic Cardiovascular Disease.
Lead sponsor
Brigham and Women's Hospital
Phase
Observational
Overall status
Completed
Start date
January 27, 2026
Completion date
June 19, 2026
Enrollment
60,000 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ascvd, overweight, type 2 diabetes